Blood Pressure Medications: Evidence-Based Treatment Approach
For most adults with confirmed hypertension (BP ≥140/90 mmHg), start with combination therapy using two first-line agents—specifically an ACE inhibitor or ARB combined with either a calcium channel blocker or thiazide diuretic—preferably as a single-pill combination. 1, 2
Initial Medication Selection
First-Line Agents (Choose Two for Most Patients)
The four proven drug classes for initial therapy are 1, 3, 4:
- ACE inhibitors (Grade A in non-Black patients)
- ARBs (Grade A-B depending on age/comorbidities)
- Dihydropyridine calcium channel blockers (Grade A-B)
- Thiazide/thiazide-like diuretics (Grade A; chlorthalidone preferred over hydrochlorothiazide) 5
Race-Based Considerations
Non-Black patients: Start with ACE inhibitor or ARB + calcium channel blocker OR + thiazide diuretic 3
Black patients: Start with ARB (not ACE inhibitor) + calcium channel blocker OR calcium channel blocker + thiazide diuretic 3
This distinction exists because ACE inhibitors show reduced efficacy as monotherapy in Black patients 4.
When to Use Monotherapy vs. Combination Therapy
Use combination therapy immediately when 4, 2:
- SBP ≥20 mmHg above target (typically ≥160 mmHg)
- DBP ≥10 mmHg above target (typically ≥100 mmHg)
- High cardiovascular risk (diabetes, CKD, established CVD)
Consider monotherapy only for 3, 1:
- Stage 1 hypertension (140-159/90-99 mmHg) with low cardiovascular risk
- Patients >80-85 years old
- Frail elderly patients
- Those at high risk for hypotension
Critical pitfall: The 2025 AHA/ACC guidelines strongly favor single-pill combinations over separate pills because adherence is significantly better, leading to fewer cardiovascular events and deaths 2. Don't prescribe multiple separate pills when a combination exists.
Dosing Strategy
Start with low doses of both agents, then titrate to full doses before adding a third drug 3. This approach maximizes efficacy while minimizing side effects.
Specific titration sequence 3:
- Start low-dose combination (e.g., ACE inhibitor/ARB + CCB or diuretic)
- Increase to full-dose combination
- Add third agent (usually the missing component: if on ACE inhibitor + CCB, add thiazide diuretic)
- If still uncontrolled, add spironolactone 25-50 mg daily (if eGFR ≥45 mL/min/1.73m² and K+ ≤4.5 mmol/L) 5, 6
Blood Pressure Targets
Target BP <130/80 mmHg for most adults 1, 5. The 2024 ESC guidelines recommend targeting systolic BP 120-129 mmHg if well-tolerated 1.
Individualize for:
- Elderly patients based on frailty (may accept <140/90 mmHg) 3, 1
- Those with orthostatic hypotension or multiple medication intolerances
- Apply "as low as reasonably achievable" (ALARA) principle when strict targets aren't tolerated 1
Monitoring Timeline
Achieve target BP within 3 months 3.
Follow-up schedule 5:
- Check basic metabolic panel 2-4 weeks after starting/titrating medications (especially diuretics, ACE inhibitors, ARBs)
- Clinic visits every 6-8 weeks during titration phase
- Once at goal: every 3-6 months depending on stability
- Use home BP monitoring to avoid hypotension (hold meds if SBP <110 mmHg) 5
Drugs to Avoid
- ACE inhibitor + ARB (Grade A—increases CVD, kidney disease, hyperkalemia)
- Two drugs from the same class (e.g., two different ACE inhibitors)
- Nondihydropyridine CCB + beta-blocker (caution—Grade D)
Not recommended as first-line 4:
- Beta-blockers for uncomplicated hypertension, especially age ≥60 years (Grade A)
- Alpha-blockers for uncomplicated hypertension (Grade A)
- ACE inhibitors in Black patients as monotherapy (Grade A)
Exception: Beta-blockers remain first-line when compelling indications exist (heart failure with reduced ejection fraction, post-MI, angina) 1.
Special Populations
Diabetes with albuminuria (ACR >2.0 mg/mmol men, >2.8 mg/mmol women): ACE inhibitor or ARB mandatory as initial therapy 7
CKD Stage 3+ or albuminuria ≥300 mg/d: ACE inhibitor preferred (ARB if intolerant); target <130/80 mmHg 5
Pregnancy: Use labetalol, methyldopa, or long-acting nifedipine; never use ACE inhibitors or ARBs (Grade C—fetotoxic) 8
Resistant Hypertension
If BP remains uncontrolled on 3 drugs (including a diuretic), consider 6:
- Spironolactone 25-50 mg daily (most effective add-on; reduces SBP by ~13 mmHg)
- Switch hydrochlorothiazide to chlorthalidone (more potent, works even with eGFR <30)
- Verify medication adherence (~50% of apparent resistance)
- Screen for secondary causes (primary aldosteronism in 5-25%)
- Assess for white-coat effect (37.5% of apparent resistance)
The evidence strongly supports spironolactone as the fourth agent, reducing 24-hour ambulatory SBP by 8.46 mmHg compared to placebo 6.
Practical Implementation
Prescribe once-daily dosing whenever possible to improve adherence 2. Most modern formulations of ACE inhibitors, ARBs, CCBs, and thiazide diuretics allow once-daily administration.
Use single-pill combinations rather than separate pills—this is not just convenient but evidence-based for reducing cardiovascular events 2.
Avoid common errors: Don't automatically discontinue thiazide diuretics when eGFR drops below 30 mL/min/1.73m² (chlorthalidone remains effective); don't underdose ACE inhibitors (flat dose-response curve means low doses have shorter duration, not less potency, causing BP fluctuations) 9.